Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16810%2F20%3A43878454" target="_blank" >RIV/62157124:16810/20:43878454 - isvavai.cz</a>
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.01047/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fonc.2020.01047/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2020.01047" target="_blank" >10.3389/fonc.2020.01047</a>
Alternative languages
Result language
angličtina
Original language name
Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
Original language description
Somatostatin analogs mantain their major role in the treatment of patients with advanced neuroendocrine tumors (NETs) and have multiple modulatory effects on the immune system. Here, we evaluated the effects of lanreotide treatment on expression of Th1, Th2 cytokine patterns in serum of patients with NETs and in bronchial and pancreatic NET cell lines. Our results showed that lanreotide treatment promoted a Th1 cytotoxic immune-phenotype in patients with NETs originated by intestinal sites. Similar results were obtained alsoin vitrowhere lanreotide induced expression of Th1 cytokines only in pancreatic and not in bronchial-derived NET cell lines. It seems, therefore, that cytokinomics can represent a useful tool for the identification of tumor biomarkers for the early diagnosis and evaluation of the response to therapy in NET patients. To avoid the drug-resistance induced by everolimus (mTOR inhibitor), we made the pancreatic NET cell line resistant to this drug. After treatment with lanreotide we found that the drug reduced its viability compared to that of sensitive cells. These data may have direct implications in design of future translation combination trial on NET patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
40301 - Veterinary science
Result continuities
Project
<a href="/en/project/NV16-28637A" target="_blank" >NV16-28637A: Bones, tendons and ligaments extent defects healing with using of new biomaterials</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Oncology
ISSN
2234-943X
e-ISSN
—
Volume of the periodical
10
Issue of the periodical within the volume
JUL
Country of publishing house
CH - SWITZERLAND
Number of pages
13
Pages from-to
—
UT code for WoS article
000555540200001
EID of the result in the Scopus database
—